November 21, 2017 / 9:49 PM / a year ago

BRIEF-‍U.S. FDA says is advising consumers not to use Limbrel​

Nov 21 (Reuters) - Food and Drug Administration-‍

* U.S. Food And Drug Administration says is advising consumers not to use limbrel​

* ‍FDA - is issuing warning on use of Limbrel because of its investigation into a rise in cases of serious adverse events​

* ‍FDA says serious adverse events from use Limbrel include drug-induced liver injury and a lung condition called hypersensitivity pneumonitis​

* ‍FDA says agency is also advising health care providers who are aware that their patients are taking Limbrel to tell them to stop using it as well​

* ‍FDA says continues to investigate Primus Pharmaceuticals and manufacturing process for Limbrel

* ‍FDA says has received a total of 194 adverse event reports regarding limbrel​

* FDA says ‍Limbrel is marketed by Primus Pharmaceuticals Inc & is available in capsule form in two dosages of Limbrel250 and Limbrel500​ Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below